EUVIMEDEUVIMED entdecken
Klinische Studie

Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study

Amelie Leutzendorff iD, Valentin Al Jalali, Martin Bauer, Iris K Minichmayr, Birgit Reiter, Michael Wölfl- Duchek, Alina Nussbaumer-Pröll, Maria Weber, Sabine Eberl, Marie Spies, Maysa Sarhan, Johannes Geilen und 3 weitere

British Journal of Clinical Pharmacology · 2025-03 · 91 (3) · 808-816

DOI: 10.1111/bcp.16274 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 21.10.2024. Verfasst von Amelie Leutzendorff und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Austria. Hauptthemen laut MEDLINE: Clomipramine, Yohimbine, Adrenergic alpha-2 Receptor Antagonists, Selective Serotonin Reuptake Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: SEROJAC PME Handels GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Clomipramine (CLOMI) has shown effectiveness in treating premature ejaculation but is linked to erectile dysfunction and reduced libido. Yohimbine (YOH), by contrast, is effective in treating erectile dysfunction and may improve libido. Combining CLOMI and YOH could potentially leverage the benefits of both drugs. This study aimed to investigate the interactions between these drugs and to evaluate their safety profile.

Methods

A prospective, open‐labelled, single‐centre, pharmacokinetic (PK) drug–drug interaction study was performed in 15 healthy male subjects. Single‐dose and steady‐state PK were investigated using noncompartmental analysis after mono‐ and combination therapy of the 2 orally applied drugs. Plasma sampling was performed at baseline, 0.5 (YOH), 1, 1.5 (YOH), 2, 3, 4, 5, 6, 8, 12 and 24 h (CLOMI). Differences in the area under the curve after multiple dosing (MD) were determined using an equivalence boundary of 80–125%.

Results

The geometric mean ratio of the area under the curve up to 12 h for MD CLOMI (combination vs . monotherapy) was 112% (90% confidence interval: 104–120%), whereas for MD YOH this ratio was 137% (90% confidence interval: 112–168%). The study drugs were safe and well tolerated as mono‐ and combination therapy, with no major adverse events reported.

Conclusion

A PK assessment of clomipramine and yohimbine indicated a clinically significant drug–drug interaction for MD YOH in combination with CLOMI. This might be explained by competitive, CLOMI‐related inhibition of YOH metabolism, probably mediated by cytochrome P450 2D6. However, according to European Medicines Agency guidelines, the effect can be classified as interaction absent (1.25–

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClomipramineYohimbineAdrenergic alpha-2 Receptor AntagonistsSelective Serotonin Reuptake InhibitorsHumansMaleDrug InteractionsAdultYoung AdultProspective StudiesArea Under CurveDrug CombinationsMiddle AgedHealthy Volunteers

Stichwörter der Autor:innen

clomipraminecombination therapydrug–drug interactionspharmacokineticsyohimbine

Substanzen

ClomipramineYohimbineAdrenergic alpha-2 Receptor AntagonistsDrug CombinationsSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Medical University of Vienna, Austria.
  • Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Austria.
  • Psychosocial Services in Vienna, Vienna, Austria.
  • Clinical Department of Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Austria.
  • Clinical Department of Cardiothoracic Vascular Anaesthesia & Intensive Care Medicine, Medical University Vienna, Austria.
  • SEROJAC PME Handels GmbH, Vienna, Austria.

ORCID-Profile: Amelie Leutzendorff, Markus Zeitlinger

Förderung

  • SEROJAC PME Handels GmbH

Zitieren

APA

Leutzendorff, A., Al Jalali, V., Bauer, M., Minichmayr, I. K., Reiter, B., Duchek, M. W., Nussbaumer-Pröll, A., Weber, M., Eberl, S., Spies, M., Sarhan, M., Geilen, J., Walther, A., Drai, D., & Zeitlinger, M. (2025). Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study. British Journal of Clinical Pharmacology, 91(3), 808-816. https://doi.org/10.1111/bcp.16274

Vancouver

Leutzendorff A, Al Jalali V, Bauer M, Minichmayr IK, Reiter B, Duchek MW, et al. Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study. British Journal of Clinical Pharmacology. 2025;91(3):808-816. doi:10.1111/bcp.16274

BibTeX
@article{Leutzendorff2025,
  author = {Leutzendorff, Amelie and Al Jalali, Valentin and Bauer, Martin and Minichmayr, Iris K and Reiter, Birgit and Duchek, Michael Wölfl- and Nussbaumer-Pröll, Alina and Weber, Maria and Eberl, Sabine and Spies, Marie and Sarhan, Maysa and Geilen, Johannes and Walther, Alexander and Drai, Daniel and Zeitlinger, Markus},
  title = {Single‐dose and steady‐state pharmacokinetics of clomipramine, yohimbine and clomipramine/yohimbine combination: A clinical drug–drug interaction study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {3},
  pages = {808--816},
  doi = {10.1111/bcp.16274}
}
Kostenlos starten →